| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. Here we use next-generation sequencing technologies to characterize the genomic and transcriptomic features of CAR-T cells and tumors that influence therapeutic responses.
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Cohort
- Total number of consented subjects: 48
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
No patients were excluded from this study.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Lymphoma, B-cell
- Immunotherapy, Adoptive
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Marcela Maus, PhD. Massachusetts General Hospital, Boston, MA, USA.
-
Funding Source
- IBM Research. Yorktown Heights, New York, USA.
-
Principal Investigator